NeuroSearch's Huntexil misses Huntington's endpoint

NeuroSearch A/S (CSE:NEUR) said twice-daily Huntexil pridopidine missed the primary endpoint of significantly improving voluntary motor function vs. placebo at week 12 in the Phase II HART trial to treat Huntington's disease (HD). The endpoint was measured by the change from baseline in the modified motor score (mMS) subscale of the Unified Huntington's Disease Rating Scale (UHDRS). The dopamine stabilizer did meet the secondary endpoint of significantly improving the total motor score of the UHDRS vs. placebo (p=0.039). The double-blind, U.S. and Canadian trial enrolled 227 patients. ...